Navigation Links
MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
Date:10/20/2010

ROCKVILLE, Md. and INDIANAPOLIS, Oct. 20 /PRNewswire-FirstCall/ -- MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the Protege Data Monitoring Committee (DMC), composed of independent experts in the fields of diabetes and biostatistics, has completed a planned analysis of one-year safety and efficacy data of the Protege Phase 3 clinical trial of teplizumab, an investigational biologic under development for the treatment of individuals with recent-onset type 1 diabetes.

The DMC concluded that the primary efficacy endpoint of the study, a composite of a patient's total daily insulin usage and HbA1c level at 12 months, was not met. The DMC, noting that all administration of experimental drug had been completed, commented that appropriate safety monitoring is warranted. No unanticipated safety issues were identified in the DMC's review.

"We will comply with the DMC's recommendations," said Scott Koenig, M.D., Ph.D., President and Chief Executive Officer, MacroGenics. "We remain committed to discovering and developing novel biologics for the treatment of autoimmune disorders like type 1 diabetes."

Following careful evaluation of the DMC's recommendations for Protege, based on the lack of efficacy, the companies have decided to suspend further enrollment and dosing of patients in two other ongoing clinical trials of teplizumab in type 1 diabetes: the Protege Encore Trial, a second Phase 3 trial of the same design as Protege, and the SUBCUE trial, a Phase 1b trial that is exploring the subcutaneous administration in patients with type 1 diabetes.

"The failure to meet the primary endpoint is obviously disappointing for the millions of people who live with and treat type 1 diabetes," said Gwen Krivi, Vice President, Product Development, Lilly Diabetes. "Lilly and MacroGenics will be considering all options for teplizumab in type 1 di
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
3. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
4. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
5. Lilly and Glenmark Pharmaceuticals Announce License Agreement
6. Lilly Receives NCQA Design Certification for Depression Care Management Program
7. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
8. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
9. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
10. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
11. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  MedScope ( www.medscope.org ), the leading ... a 2015 Connected World magazine Connected World ... (mPERS), that can be used anywhere, anytime. The nomination ... In nominating MedScope, Landon Garner , ...
(Date:1/23/2015)... and DUBLIN , Jan. 23, ... agreement with KRS Global Biotechnology, Inc. for the compounding, packaging ... compounded for shipment in the United States ... approved Outsourcing Facility capable of compounding naltrexone tablets in various ...
(Date:1/23/2015)... 2015  Pete Rose, baseball,s all-time hits leader, is the new ... Myoflex, Ducere Pharma has announced. "Pete,s a Hall ... have him on board with Myoflex," said Ducere Pharma Chief ... player who is known across all generations. The passion and ...
Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4Pete Rose bets on Myoflex to relieve aches and pains 2
... 6, 2012  PAREXEL International Corporation (NASDAQ: PRXL ... that Ramita Tandon, Global Head, Late Phase Clinical Trials ... Operations at PAREXEL will address innovative approaches to late ... ( SCOPE ), to be held February 7-9, 2012 ...
... New York, February 6, 2012 In the news ... of USD 6.8 billion in 2015, China Osteoporosis Market Will be ... 11:30 GMT, by Transparency Market Research over PR Newswire, we are ... "Market Size of USD 6.8 billion" has been changed to "Market ...
Cached Medicine Technology:PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives 2PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives 3PAREXEL to Address Innovative Approaches to Late Stage Development at Summit for Clinical Ops Executives 4CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015 2CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015 3CORRECTION - Transparency Market Research: Global Osteoporosis Market is Expected to Attain a Market Size of USD 11.4 billion in 2015, China Osteoporosis Market Will be Worth USD 2.5 Billion in 2015 4
(Date:1/22/2015)... (PRWEB) January 22, 2015 Gabe’s Chemo Duck Program ... App, the first app ever created for kids with cancer. The ... phones and devices, is filled with enjoyable games to help children ... treatments. The free app helps to keep kids entertained, educated and ...
(Date:1/22/2015)... Houston, TX (PRWEB) January 22, 2015 The ... Pro Bodybuilder Ben Pakulski to increase lean muscle by up ... This has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting ... shows that it is a step-by-step, scientific diet formula that ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, ... dresses. View website of AngelWeddingDress.com to find ... wedding dresses online for a bridal party. AngelWeddingDress offers ... for them. Its maternity wedding dresses are specially designed ...
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz ... has treated just about every type of injury that can result ... those same twenty-plus years, the team at Doctors on Liens ... best possible doctor. With the combined breadth of experience ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... and adolescence can cause abnormal development of the femur ... reduced rotation and pain during movement. This may explain ... more sedentary individuals, according to Dr. Klaus Siebenrock, from ... work is published online in Springer,s journal Clinical ...
... TUESDAY, July 19 (HealthDay News) -- Older adults who keep ... their mental abilities, two new studies suggest. Both reports ... Internal Medicine , to coincide with presentations scheduled to be ... Paris. "We looked at an objective measure of physical ...
... of the University of Granada and Edimbourgh have developed ... might improve significantly chemotherapy, as it has not cause ... encapsulation of a catalyst (palladium) into microspheres, to synthesize ... avoiding any toxicity. This system captures palladium within its ...
... A group of French scientists (from the Unit of ... Research, Bobigny, France; the French Institute for Prevention and ... Cancer Institute) have published a paper in the ... guidelines for drinking and the relation of alcohol to ...
... HealthDay Reporter , MONDAY, July 18 (HealthDay News) -- ... have radically improved the life expectancy of HIV-infected patients ... that when made affordable and accessible, the same drug ... finding stems from a Canadian research team,s investigation -- ...
... French . A new study that ... of congenital hypothyroidism in the United States, and aimed at ... that the increase is entirely artifactual. CH is characterized by ... of preventable intellectual disability. The results were published in the ...
Cached Medicine News:Health News:Painful legacy of teen sports 2Health News:More Evidence That Exercise May Keep The Brain Sharp 2Health News:More Evidence That Exercise May Keep The Brain Sharp 3Health News:A new therapy without side effects could improve dramatically chemotherapy 2Health News:Are drinking guidelines adequate regarding the risk of cancer? 2Health News:Are drinking guidelines adequate regarding the risk of cancer? 3Health News: Drugs Can Bring HIV-Infected Africans Normal Life Spans 2Health News: Drugs Can Bring HIV-Infected Africans Normal Life Spans 3Health News: Drugs Can Bring HIV-Infected Africans Normal Life Spans 4Health News:No increase in commonest preventable cause of intellectual disability over 20 years 2
... Mesh Self-Forming Plug is a mesh plug ... well as primary inguinal hernias and femoralhernias. ... defect and fills it completely. Premilene Mesh ... of the established Premilene Mesh. The plug ...
... The Celsius Control System provides ... can safely,and rapidly lower patient ... target temperature and,rewarm patients to ... System consists of an endovascular,catheter, ...
... lightsource , it maximizes use by ... from it, while the third lamp ... managed care in mind, it includes ... cables. An excellent choice for hospital ...
... the patented Orion incorporates superior optics in ... The fully adjustable headband, made of ... low on the brow, directing the spot ... clips on the headband position the cable ...
Medicine Products: